Silence Therapeutics price to book ratio SLN

Market value divided by the book value of the company's net assets, since 2025.

Today, Oct 23, 2026: 24.2×
Peer median: 2.5×

Silence Therapeutics' price to book ratio is 24.2× as of Oct 23, 2026.

The median for 10 large drugmakers of a similar size is 2.5×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	24.2×	2.8×	24.2×
2025	4.0×	0.9×	4.4×

Against its peers

Companies in Drug Manufacturers - General nearest Silence Therapeutics' size, closest first, today.

Company	Price to book ratio
SLNSilence Therapeutics	24.2×
ABUSArbutus Biopharma	3.2×
AMPHAmphastar Pharmaceuticals	1.4×
COLLCollegium Pharmaceutical	2.4×
OMEROmeros	n/m
CRMDCorMedix	1.3×
PCRXPacira BioSciences	2.2×
ANABAnaptysbio	138×
ZVRAZevra Therapeutics	2.7×
IRWDIronwood Pharmaceuticals	n/m
PBYIPuma Biotechnology	4.1×
Peer median	2.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Silence Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.